期刊文献+

HBV感染慢性肝病患者血清GP73浓度对肝纤维化程度的诊断意义 被引量:5

The relationship between serum GP73 concentration and HBV chronic liver hardness
原文传递
导出
摘要 目的 探讨血清GP73浓度与慢性HBV肝病患者肝纤维化程度之间的关系,以评估GP73在慢性HBV患者中的临床诊断价值.方法 选取慢性HBV感染者761名,分别进行FibroScan检测和血清GP73测试.结果 血清GP73浓度与肝硬度相关(r=0.601),ROC曲线下面积为0.76.GP73用于诊断显著肝纤维化(≥F2)的敏感性和特异性分别为62.81%和80.05%(cut off值:76.6ng/ml).结论 GP73可能是一种诊断慢性HBV感染者显著肝纤维化的新标志物. Objective To investigate the relationship between serum concentration of GP73 and liver stiffness in chronic HBV liver disease, to evaluate clinical diagnostic value of GP73 in chronic HBV patients. Methods 761 patients with chronic HBV infection took liver stiffness measurement, and all patients had serum GP73 test. Results The concentration of serum GP73 and liver stiffness was related ( r = 0. 601 ) , area under the ROC curve was 0. 76. GP73 for the diagnosis of significant fibrosis ( ≥ F2) the sensitivity and specificity were 62. 81% and 80.05% ( cut off: 76.6 ng/ml). Conclusion GP73 may be a marker for diagnosis of chronic HBV infection significant liver fibrosis.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 2014年第1期44-46,共3页 Chinese Journal of Experimental and Clinical Virology
基金 首都医学发展基金重点项目(2005-2038),首都临床特色应用研究(Z111107058811068)
关键词 肝炎病毒 乙型 高尔基体 肝硬化 Hepestitis B Golgi apparatus Liver cirrhosis
  • 相关文献

参考文献9

  • 1Teixeira-Clerc F,Julien B,Grenard P. CBI cannabinoid receptor antagonism:a new strategy for the treatment of liver fibrosis[J].{H}Nature Medicine,2006.671-696.
  • 2Tong MJ,Hsien C,Hsu L. Treatment recommendations for chronic hepatitis B:an evaluation of current guidelines based on a natural history study in the United States[J].{H}HEPATOLOGY,2008.1070-1078.
  • 3Hoefs JC,Shiffman ML,Goodman ZD. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C:results from the HALT-C Trial[J].{H}GASTROENTEROLOGY,2011.900-908.e1-2.
  • 4Riener MO,Stenner F,Liewen H. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas[J].{H}HEPATOLOGY,2009.1602-1609.
  • 5LiuX,Wan X,Li Z. Golgi protein 73(GP73),a useful serum marker in liver diseases[J].{H}Clinical Chemistry and Laboratory Medicine,2011.1311-1316.
  • 6Iftikhar R,Kladney RD,Havlioglu N. Disease-and cellspecific expression of GP73 in human liver disease[J].{H}American Journal of Gastroenterology,2004.1087-1095.
  • 7侯俊,郭桐生,赵静,刘爱霞,宋永继,郭静霞,刘佳,陈霖,徐军,魏红山,李伯安.高尔基体蛋白73定量检测方法的建立[J].中华实验和临床病毒学杂志,2013,27(5):382-384. 被引量:4
  • 8Adams LA,George J,Bugianesi E. Complex non-invasive fibrosis models are more accurate than simple models in nonalcoholic fatty liver disease[J].{H}Journal of Gastroenterology and Hepatology,2011.1536-1543.
  • 9Poynard T,Ngo Y,Perazzo H. Prognostic value of liver fibrosis biomarkers:a meta-analysis[J].Gastroenterol Hepatol (N Y),2011.445-454.

二级参考文献5

  • 1Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver uhrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev, 2012,12:9 ( CD002799 ).
  • 2Kladney RD, Bulla GA, Guo L et al. GP73, a novel Golgi- localized protein upregulated by viral infection. Gene,2000,249 : 53-65.
  • 3Zhou Y, Yin X, Ying J, et al. Golgi protein 73 versus alpha- fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer, 2012,16 : 12-17.
  • 4Ba MC, Long H, Tang YQ, et al. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int J Clin Exp Pathol,2012 ,5 :874-881.
  • 5Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci, 2010,55:2744-2755.

共引文献3

同被引文献57

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部